MILAN, August 04, 2023--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended June 30, 2023, and provided an update on its R&D and business activities.
MILAN, May 15, 2023--Newron presents exciting new data from two international medical conferences on its Phase II trial of evenamide for treatment resistant schizophrenia
MILAN, May 03, 2023--Newron to present further data from its study 014/015 on evenamide for treatment resistant schizophrenia at two international congresses in May 2023.